Heat shock protein 27: clue to understanding estrogen-mediated atheroprotection?

Trends in Cardiovascular Medicine
Katey RaynerEdward R O'Brien

Abstract

Although the use of estrogen replacement therapy for postmenopausal women has been dramatically curtailed due to an unfavorable risk-benefit profile, there remains strong experimental evidence that ovarian hormones have a favorable effect on vessel wall homeostasis. We recently discovered that release of heat shock protein 27 (HSP27) into the serum is atheroprotective and mediated by ovarian hormones, preferentially functioning via estrogen receptor-beta. HSP27 binds scavenger receptor-A, reduces cholesterol uptake in macrophages, and attenuates mediators of vascular inflammation. Therefore, it is attractive to consider HSP27 as the active foot soldier of estrogens and potentially a novel therapeutic opportunity for vascular disease.

References

Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·P A BourassaR J Aiello
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·B HansteinM Brown
Jun 11, 1999·The New England Journal of Medicine·M E Mendelsohn, R H Karas
Jul 19, 2002·JAMA : the Journal of the American Medical Association·Jacques E RossouwUNKNOWN Writing Group for the Women's Health Initiative Investigators
Nov 20, 2004·Science·Karine M EganGarret A Fitzgerald
Apr 13, 2006·The Journal of Clinical Endocrinology and Metabolism·Rose C ChristianLorraine A Fitzpatrick
Apr 5, 2007·JAMA : the Journal of the American Medical Association·Jacques E RossouwMarcia L Stefanick
Sep 18, 2007·Molecular Endocrinology·Carolyn D DuSellDonald P McDonnell
Sep 22, 2007·Current Opinion in Lipidology·Jean-François ArnalPierre Gourdy
Jul 23, 2008·Perspectives in Vascular Surgery and Endovascular Therapy·Kimon Bekelis, Nicos Labropoulos
Aug 15, 2008·Molecular Endocrinology·Bert W O'Malley, Neil J McKenna
Feb 24, 2009·Primary Care·Alan M Weiss
Aug 6, 2009·Journal of Cardiovascular Translational Research·Amparo C VillablancaJohn C Rutledge
Oct 28, 2009·Archives of Internal Medicine·Amytis TowfighiBruce Ovbiagele
Apr 23, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aurélie DocquierVincent Cavaillès
Jun 24, 2011·Journal of Cardiovascular Pharmacology·Jiangfeng SunEdward O'Brien

❮ Previous
Next ❯

Citations

Aug 14, 2013·Research in Veterinary Science·Melisa M L VelázquezHugo H Ortega
Nov 8, 2011·American Journal of Physiology. Heart and Circulatory Physiology·Qingbo XuKaushik Mandal
Jan 12, 2012·The International Journal of Biochemistry & Cell Biology·Johannes M van NoortSandra Amor
Jan 31, 2012·International Journal of Pharmaceutics·Stephane RochePaul C Schiller
Sep 13, 2011·Cell Metabolism·Rodrigo P A Barros, Jan-Åke Gustafsson
Jan 4, 2015·Biochimica Et Biophysica Acta·Raman BakthisaranCh Mohan Rao
Aug 11, 2011·Journal of Molecular Endocrinology·Michael P CorcoranStefania Lamon-Fava
Oct 4, 2013·Expert Review of Proteomics·María Insenser, Héctor F Escobar-Morreale
Oct 22, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Xiaoli MaEdward R O'Brien
Nov 6, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tawanda ZiningaAddmore Shonhai
Jul 15, 2020·Journal of Cardiovascular Translational Research·Jose A Inia, Edward R O'Brien
Dec 19, 2018·BMC Nephrology·Andrzej JaroszyńskiWojciech Dąbrowski
Oct 8, 2020·Metabolites·Haoxin ZhaoStanley Ching-Cheng Huang
Aug 28, 2021·Cells·Carolina Victória Cruz JunhoMarcela Sorelli Carneiro-Ramos

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.